With the broader availability of data, both on drugs and patients, as well as better sources of data in emerging markets, through both public and proprietary sources, life science companies are applying it in both portfolio and product investment decisions. What data are companies using and what new insights do they find most valuable? What capabilities are needed to maximize the value of large data sets (patient-reported data, real-world data, protein modeling data, drug-development data, etc.) and what new challenges do they present? This panel will examine data and decision-making in drug development from multiple perspectives.
Panel Chair: David Wolter